Chemistry company Evotec OAI has announced a £1.7m one-year deal with Swiss biotech company Serono.
Scientists from Evotech OAI at Milton Park, near Abingdon, and in Hamburg will find compounds which can be used for Serono's drug discovery projects.
As well as the £1.7m fee, Evotec OAI will receive milestone payments if its compounds are patented and enter clinical trials.
The collaboration with Serono, dating from October 1998, has grown into a long-term discovery and development partnership.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article